FR3010999B1 - Glycoclusters et leurs utilisations pharmaceutiques en tant qu'antibacteriens - Google Patents

Glycoclusters et leurs utilisations pharmaceutiques en tant qu'antibacteriens

Info

Publication number
FR3010999B1
FR3010999B1 FR1452355A FR1452355A FR3010999B1 FR 3010999 B1 FR3010999 B1 FR 3010999B1 FR 1452355 A FR1452355 A FR 1452355A FR 1452355 A FR1452355 A FR 1452355A FR 3010999 B1 FR3010999 B1 FR 3010999B1
Authority
FR
France
Prior art keywords
antibacterians
glycoclusters
pharmaceutical uses
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1452355A
Other languages
English (en)
Other versions
FR3010999A1 (fr
Inventor
Francois Morvan
Jean-Jacques Vasseur
Caroline Ligeour
Yann Chevolot
Eliane Souteyrand
Olivier Vidal
Alice Goudot
Sebastien Vidal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Montpellier
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Montpellier I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Montpellier I filed Critical Centre National de la Recherche Scientifique CNRS
Priority to JP2016517519A priority Critical patent/JP6595460B2/ja
Priority to ES14771331.7T priority patent/ES2656004T3/es
Priority to US15/023,470 priority patent/US10105380B2/en
Priority to EP14771331.7A priority patent/EP3049426B1/fr
Priority to PCT/EP2014/070110 priority patent/WO2015040209A1/fr
Priority to CA2925028A priority patent/CA2925028A1/fr
Publication of FR3010999A1 publication Critical patent/FR3010999A1/fr
Application granted granted Critical
Publication of FR3010999B1 publication Critical patent/FR3010999B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1452355A 2013-09-23 2014-03-21 Glycoclusters et leurs utilisations pharmaceutiques en tant qu'antibacteriens Expired - Fee Related FR3010999B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2016517519A JP6595460B2 (ja) 2013-09-23 2014-09-22 糖鎖クラスター及び抗菌剤としてのその医薬の使用
ES14771331.7T ES2656004T3 (es) 2013-09-23 2014-09-22 Glicoclusters y su uso farmacéutico como antibacterianos
US15/023,470 US10105380B2 (en) 2013-09-23 2014-09-22 Glycoclusters and their pharmaceutical use as antibacterials
EP14771331.7A EP3049426B1 (fr) 2013-09-23 2014-09-22 Glycoclusters et leur utilisation pharmaceutique comme antibactériens
PCT/EP2014/070110 WO2015040209A1 (fr) 2013-09-23 2014-09-22 Glycoclusters et leur utilisation pharmaceutique comme antibactériens
CA2925028A CA2925028A1 (fr) 2013-09-23 2014-09-22 Glycoclusters et leur utilisation pharmaceutique comme antibacteriens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306296.8A EP2851371A1 (fr) 2013-09-23 2013-09-23 Glycoclusters et leur utilisation pharmaceutique comme antibactériens

Publications (2)

Publication Number Publication Date
FR3010999A1 FR3010999A1 (fr) 2015-03-27
FR3010999B1 true FR3010999B1 (fr) 2017-06-16

Family

ID=49326619

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1452355A Expired - Fee Related FR3010999B1 (fr) 2013-09-23 2014-03-21 Glycoclusters et leurs utilisations pharmaceutiques en tant qu'antibacteriens

Country Status (7)

Country Link
US (1) US10105380B2 (fr)
EP (2) EP2851371A1 (fr)
JP (1) JP6595460B2 (fr)
CA (1) CA2925028A1 (fr)
ES (1) ES2656004T3 (fr)
FR (1) FR3010999B1 (fr)
WO (1) WO2015040209A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2851371A1 (fr) * 2013-09-23 2015-03-25 Centre National de la Recherche Scientifique (CNRS) Glycoclusters et leur utilisation pharmaceutique comme antibactériens

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011158068A1 (fr) * 2010-06-18 2011-12-22 Centre National De La Recherche Scientifique (Cnrs) Structure moléculaire non covalente, dispositif la comprenant et son utilisation pour la détection d'une lectine
JP5774120B2 (ja) * 2010-12-10 2015-09-02 サーントル ナシオナル ドゥ ラ ルシェルシェ シャーンティフィク 病原体レクチンに対する抗感染性としてのグリコミメティック化合物
JP2014521081A (ja) * 2011-07-12 2014-08-25 サーントル ナシオナル ドゥ ラ ルシェルシェ シャーンティフィク（セーエンヌエールエス） ピレン系糖複合体を含む非共有結合性分子構造体、それを含む装置、及びレクチンを検出するためのその使用
EP2851371A1 (fr) * 2013-09-23 2015-03-25 Centre National de la Recherche Scientifique (CNRS) Glycoclusters et leur utilisation pharmaceutique comme antibactériens

Also Published As

Publication number Publication date
US10105380B2 (en) 2018-10-23
FR3010999A1 (fr) 2015-03-27
JP6595460B2 (ja) 2019-10-23
WO2015040209A1 (fr) 2015-03-26
EP3049426B1 (fr) 2017-11-01
EP3049426A1 (fr) 2016-08-03
US20160287620A1 (en) 2016-10-06
CA2925028A1 (fr) 2015-03-26
ES2656004T3 (es) 2018-02-22
EP2851371A1 (fr) 2015-03-25
JP2016533342A (ja) 2016-10-27

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA42950A (fr) Administration d'agents de potentialisation de cftr modifiés au deutérium
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA50541A (fr) Formulations pharmaceutiques
FR2993565B1 (fr) Composes fluorescents de type thienyldipyrromethene bores et leurs utilisations.
MA44665A (fr) Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
MA42303A (fr) Formulations pharmaceutiques
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA46867A (fr) Formulations pharmaceutiques
MA50678A (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
MA44968A (fr) Esters d'oxaborole et leurs utilisations
BR112016011430A2 (pt) agentes anticâncer e preparação dos mesmos.
DK3079655T3 (da) Inhalerbare lægemidler
MA46901A (fr) Agents psychotropes et leurs utilisations
MA46562A (fr) Anticorps anti-chikv et leurs utilisations
MA45411A (fr) Compositions antimalariques et leurs utilisations
MA41850A (fr) Nouvelles utilisations pharmaceutiques
MA41171A (fr) Acides pyridyl-cycloalkyl-carboxylic substitués, compositions les contenant et leurs utilisations médicales
FR3005663B1 (fr) Lyophilisat de ver marin et ses utilisations
DK2897588T3 (da) Inhalerbart lægemiddel
MA45715A (fr) Anticorps anti-hspa5 (grp78) et leurs utilisations

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

TQ Partial transmission of property

Owner name: UNIVERSITE DE MONTPELLIER, FR

Effective date: 20211228

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (, FR

Effective date: 20211228

ST Notification of lapse

Effective date: 20221105